Acadia snags Amgen, Horizon vet to direct R&D; Samantha Truex steps down as Upstream Bio CEO

→ Just a few weeks after Amgen touted its efforts in rare disease, EVP of R&D in that therapeutic area is departing to lead R&D at Acadia Pharmaceuticals. Elizabeth Thompson will steer research and development at the neuroscience drugmaker after serving in key roles on the pre- and post-marketing work of Horizon’s medicines. She contributed to Tepezza, Krystexxa and Uplizna, among other drugs, during her time at the Chicago and Ireland biopharma, which Amgen bought last year for nearly $28 billion. She joins Acadia about 13 months after it secured its second FDA approval. Her career includes a prior 10-year tenure at Amgen and roles at InterMune, Raptor and AbbVie.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。